NIPRO

Corporate InformationHistory

The following is a brief history of NIPRO, from its founding to today.

1994–2003

Expansion of Injection Kits

During this period, NIPRO accelerated its global business expansion by establishing business bases in quick succession, including locations in China, Brazil, the United States, and Singapore.
In 1996, the company was listed on the First Section of the Tokyo Stock Exchange. The company focused on the research and development of medical devices and pharmaceuticals, and also developed infusion kits in succession by combining its technologies.

1994
The company acquired Hishiyama Pharmaceutical Corporation as a subsidiary. The company also launched half-type kits.
Nipro (Shanghai) Co., Ltd. was established in China.
1995
The company launched integrated kits.
Nipro Medical Ltda. was established in Brazil.
Nipro Medical Ltda.
1996
Nipro Medical Corporation was established in the U.S.
The company was listed on the First Section of the Tokyo Stock Exchange.
1997
The company launched sodium hyaluronate pre-filled syringes.
Nissho Nipro Asia Pte Ltd (current Nipro Asia Pte Ltd) was established in Singapore.
1998
Pharmaceutical Research Center was constructed in Kusatsu, Shiga Prefecture.
The company acquired capital in Makino Pharmacy Co., Ltd. (corporate name changed to Nissho Drug Co., Ltd. in the same year).
Pharmaceutical Research Center
2001
The company changed its corporate name to NIPRO CORPORATION. Store Section was spun off to Nissho Corporation.
2002
Hishiyama Pharmaceutical Corporation Odate Plant (current Nipro Pharma Corporation Odate Plant) was constructed.
The company began contract manufacturing of pre-filled syringes for dialysis.
Hishiyama Pharmaceutical Corporation Odate Plant (current Nipro Pharma Corporation Odate Plant)
2003
Hishiyama Pharmaceutical Corporation changed its name to Nipro Pharma Corporation.
Nipro Trading (Shanghai) Co., Ltd. was established in China.

2004–

Focusing Resources on the Medical Field

NIPRO has been focusing its management resources on the medical field, and actively promoting capital investment, alliances, and M&A. By integrating the three technologies of medical devices, pharmaceuticals, and glass, the company has been making efforts to expand its product lineup and increase its share of the global market.

2004
Apr.
The company acquired capital in Takeshima Pharmaceutical Corporation (current Nipro Pharma Corporation Saitama Site).
2005
Apr.
The company acquired the cardiopulmonary bypass section of Dainippon Ink and Chemicals, and fully entered into the oxygenator business.
Jun.
The company acquired Tohoku Chugai Pharmaceutical Co., Ltd. (current Nipro Pharma Corporation Kagamiishi Plant) to expand its business to solid formulations.
Full entry into the oxygenator business
2006
Apr.
The company acquired capital in Zensei Pharmaceutical Industries Co., Ltd.
Jul.
The company transferred all shares of Nissho Corporation to Hankyu Department Stores, Inc.
Aug.
The company acquired the cardiopulmonary bypass section of Edwards Lifesciences Corporation in the United States to promote the global expansion of the oxygenator business.
Oct.
The company transferred the shares of Nissho Drug Co., Ltd. held by NIPRO to Kirindo Co., Ltd., clarifying its policy of concentrating its management resources on its core business (medical devices and pharmaceuticals).
2007
May
The company acquired Saitama Daiichi Pharmaceutical Corporation (current Nipro Pharma Corporation Plant 2 and 3, Saitama Site) to expand its business to transdermal systems.
Jun.
The company began integrated production, from the spinning of hollow fiber membranes to the production of dialyzers, at the Odate Factory.
Start of transdermal systems business
2008
Oct.
The company developed partnerships with ReproCELL Inc. and Cell Science & Technology Institute, Inc. to develop joint business and expand the lineup of culture-medium-related products using ES/iPS cells and somatic stem cells.
2010
Feb.
Nipro India Corporation Private Limited and Nipro Glass India Pvt Ltd (current Nipro PharmaPackaging India Private Limited) were established in India.
Mar.
The company acquired Home Diagnostics, Inc. (currently named Nipro Diagnostics, Inc.) in the United States as a subsidiary to expand its overseas diabetes-related business.
Sep.
The company acquired capital in Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd. was established to expand its business to medical glass in China.
Oct.
The company acquired capital in Nipro Medical (Hefei) Co., Ltd. to expand its business for the purpose of the production of medical devices in China.
Nov.
The company acquired capital in Jilin Nipro Jiaheng Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
Nipro India Corporation Private Limited
2011
Jan.
The company acquired capital in Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
Feb.
PT. NIPRO INDONESIA JAYA was established in Indonesia.
Mar.
The company acquired JMI Company Ltd. (current Nipro JMI Company Ltd.) to expand its medical business in Bangladesh.
Apr.
The company acquired Tube Glass Containers Ltd. (current Nipro PharmaPackaging India Private Limited) to expand its business to medical glass in India.
PT. NIPRO INDONESIA JAYA
Jul.
The company purchased medical glass business in France (current Nipro PharmaPackaging France S.A.S), Belgium (current Nipro PharmaPackaging Belgium N.V.), and the U.S. (current Nipro PharmaPackaging Americas Corp.) from Amcor Limited to expand its medical glass business.
Aug.
The company acquired Nipro Pharma Glass AG, its holding company in Switzerland, to expand its medical glass business in Russia.
2012
Jan.
The company acquired JMI Pharma Ltd. (current Nipro JMI Pharma Ltd.) to launch its pharmaceutical business in Bangladesh.
Apr.
The company purchased MGlas AG (current Nipro PharmaPackaging Germany GmbH) and MG Sterile Products AG (current Nipro PharmaPackaging Germany GmbH) to expand its medical glass business in Germany.
2013
Mar.
The company acquired Goodman Co., Ltd. to enhance its cardiovascular business.
Jul.
The company acquired capital in Infraredx Inc. to expand its cardiovascular business in the U.S.
Dec.
Nipro Amtes Co., Ltd. was established for production of medical electronic devices.
Nipro Amtes Co., Ltd.
2014
Mar.
The company acquired Cell Science & Technology Institute, Inc. to enhance its cell culture business.
Jun.
Biwako Factory was newly built in Kusatsu, Shiga Prefecture as a mother factory for glass business. Otsu Factory was transferred to the new factory.
Oct.
The company opened NIPRO iMEP, a medical training facility, in Kusatsu, Shiga Prefecture.
Medical training facility NIPRO iMEP
2015
Apr.
The medical business of Unitika Ltd. was transferred to the company to enhance its test drug business.
Oct.
The company acquired Infraredx, Inc. to enhance its cardiovascular business in the U.S.
Nipro PharmaPackaging (Shanghai) Co., Ltd. was established for the purpose of developing medical glass business in China.
2016
Jan.
The company transferred all shares of Nipro Diagnostics, Inc. to Sinocare, Inc. in China.
Jun.
Nipro System Software Engineering Co., Ltd. was established for the purposes of development, manufacturing, and sales of systems such as medical software.
Dec.
The company opened the Research and Development Center for Regenerative Medicine.
2017
Jan.
The company acquired NexMed International Co., Ltd. as a subsidiary to expand its orthopedics business.
Jan.
The company acquired capital in Transonic Japan Co., Ltd. (current Nipro Transonic Co., Ltd.) to expand its orthopedics business.
Mar.
The company established Nipro Vietnam Company Limited in Vietnam to manufacture medical devices.
Apr.
Nipro Pharma Corporation absorbed Nipro Patch Co., Ltd.
Oct.
The company acquired Tanabe Pharma Sales Co., Ltd. (current Nipro ES Pharma Co., Ltd.) as a subsidiary to expand the generic drugs of its own brand.
2018
Feb.
The company acquired Machida Endoscope Co., Ltd. as a subsidiary to expand its business to endoscope related business.
Apr.
The company merged the sales organization of Goodman Co., Ltd. with our Vascular Division to expand its vascular business.
2019
Feb.
Nipro (China) Holdings Co., Ltd was established to strengthen business management and efficient use of management resources in China.
Mar.
Nipro Pharma Corporation purchased Kasukabe Plant (current Nipro Pharma Saitama Site) from Nihon Generic Co., Ltd.
Apr.
Nipro Pharma Corporation acquired Tanabe Seiyaku Yoshiki Factory Co., Ltd. (current Nipro Pharma Hida Factory Corporation).
Apr.
The company merged the sales organization of Nipro ES Pharma Co., Ltd. with our Domestic Division to expand its pharmaceutical business.
Jul.
The company acquired JMI Syringes & Medical Devices Limited to enhance its medical business in Bangladesh.
Nov.
The company acquired JMI Marketing (current NIPRO JMI Medical Ltd.) to enhance its medical business in Bangladesh.
Dec.
The company acquired NephroFlow N.V. (current Nipro Digital Technologies Europe) to enhance its development of software for dialysis information management systems in Europe.
Dec.
The company established Nipro Renal Solutions USA Corporation in the United States to manufacture dialytic fluid.
2020
Mar.
The company established Nipro Medical Morocco SARL in Morocco to strengthen sales of medical devices in Morocco and West Africa.
Jul.
The company acquired MTN Neubrandenburg GmbH in Germany to enhance its dialytic fluid business in Germany and eastern Europe.
2021
Apr.
The company acquired Piramida d.o.o. (current Nipro PharmaPackaging Croatia LLC) in Croatia to enhance its manufacturing and sales of glass containers for medical use in central Europe.
Jul.
The company established Nipro Sales Vietnam Limited for the purpose of selling medical equipment in Vietnam.
Aug.
The company established Nipro Holding Americas, Inc. to strengthen management control of entities located in the Americas and to efficiently utilize management resources.
Dec.
Nipro Medical Philippines Corp. was established to handle sales of medical devices and to provide an in-house dialysis center in the Philippines.
2022
Apr.
Following market classification revisions of the Tokyo Stock Exchange, the company was moved from the First Section to the Prime Market.
2023
Apr.
Head office functions were transferred to 3-26, Senriokashinmachi, Settsu, Osaka, Japan.

From 1947 to 1963 – From 1984 to 1993